4-氯-3-氟-苯丙酸 | 881189-65-7

• 分子结构分类: 有机化合物 - 苯丙烷和聚酮 - 苯丙酸
• 中文名称: 4-氯-3-氟-苯丙酸
• 中文别名: 3-(4-氯-3-氟苯基)丙酸
• 英文名称: 3-(4-chloro-3-fluorophenyl)propanoic acid
• 英文别名: 3-(4-chloro-3-fluoro-phenyl)-propionic acid；3-(4-Chloro-3-fluorophenyl)propionic acid
• CAS: 881189-65-7
• 化学式: C₉H₈ClFO₂
• 分子量: 202.613
• InChiKey: GDXMVKNNJGWZFN-UHFFFAOYSA-N

物化性质

• 熔点：
  80-84℃

计算性质

• 辛醇/水分配系数(LogP)：
  2.4
• 重原子数：
  13
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.22
• 拓扑面积：
  37.3
• 氢给体数：
  1
• 氢受体数：
  3

安全信息

• 危险性防范说明：
  P261,P305+P351+P338
• 危险性描述：
  H315,H319,H335

SDS

Material Safety Data Sheet

---

Section 1. Identification of the substance
3-(4-Chloro-3-fluorophenyl)propionic acid
Product Name:
Synonyms:

---

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.
H315: Causes skin irritation
H319: Causes serious eye irritation
H335: May cause respiratory irritation
P261: Avoid breathing dust/fume/gas/mist/vapours/spray
Wear protective gloves/protective clothing/eye protection/face protection
P280:
P305+P351+P338: IF IN EYES: Rinse cautiously with water for several minutes. Remove contact lenses if present
and easy to do – continue rinsing
P304+P340: IF INHALED: Remove victim to fresh air and keep at rest in a position comfortable for breathing
P405: Store locked up

---

Section 3. Composition/information on ingredients.
3-(4-Chloro-3-fluorophenyl)propionic acid
Ingredient name:
CAS number: 881189-65-7

---

Section 4. First aid measures
Immediately wash skin with copious amounts of water for at least 15 minutes while removing
Skin contact:
contaminated clothing and shoes. If irritation persists, seek medical attention.
Eye contact: Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.
Ingestion:

---

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

---

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

---

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Storage: Store in closed vessels.

---

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

---

Section 9. Physical and chemical properties
Not specified
Appearance:
Boiling point: No data
Melting point: No data
Flash point: No data
Density: No data
Molecular formula: C9H8ClFO2
Molecular weight: 202.6

---

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide, hydrogen chloride, hydrogen fluoride.

---

Section 11. Toxicological information
No data.

---

Section 12. Ecological information
No data.

---

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

---

Section 14. Transportation information
Non-harzardous for air and ground transportation.

---

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  4-氯-3-氟-苯丙酸 在 正丁基锂 、 草酰氯 、 双氧水 、 N,N-二异丙基乙胺 、 N,N-二甲基甲酰胺 、 Methanaminium,N-[(dimethylamino)(3H-1,2,3-triazolo[4,5-b]pyridin-3-yloxy)methylene]-N-methyl-, hexafluorophosphate(1-) 、 lithium hexamethyldisilazane 作用下， 以 四氢呋喃 、 二氯甲烷 、 水 、 N,N-二甲基甲酰胺 为溶剂， 反应 84.53h， 生成 tert-butyl (S)-3-((2-((R)-3-(4-chloro-3-fluorophenyl)-2-methylpropanamido)-4-(3,5-dimethylisoxazol-4-yl)phenyl)amino)pyrrolidine-1-carboxylate
  参考文献：
  名称：

  [EN] ISOXAZOLYL SUBSTITUTED BENZIMIDAZOLES
  [FR] BENZIMIDAZOLES SUBSTITUÉS PAR UN ISOXAZOLYLE

  摘要：

  一种化合物，是一种具有以下结构的苯并咪唑基异唑烷（I）：其中：R0和R，相同或不同，分别为H或C1-6烷基；R9，R9和R9，相同或不同，分别为H或F；X为-(烷基-，-烷基-C(=O)-NR-，-烷基-NR-C(=O)-或-烷基-C(=O)-；R1从-S(=O)2R'，未取代或取代的4-至6-成员的C-连接的杂环基，以及以下式的N-连接的螺环基中选择：R2和R2'，相同或不同，分别为H或C1-6烷基，或者R2和R2'与它们连接的C原子一起形成C3-6环烷基；R3和R3，相同或不同，分别为H，C1-6烷基，OH或F；R4为苯基或未取代或取代的含氮5-至12-成员的杂芳基；烷基为C1-6烷基；R'为C1-6烷基；n为0或1；或其药用盐。该化合物具有调节p300和/或CBP活性的作用，并用于治疗癌症，特别是前列腺癌。

  公开号：

  WO2016170324A1
• 作为产物：
  描述：

  4-氯-3-氟肉桂酸 在 palladium 10% on activated carbon 、 zinc dibromide 氢气 作用下， 以 甲醇 为溶剂， 20.0 ℃ 、101.33 kPa 条件下， 反应 14.0h， 以99%的产率得到4-氯-3-氟-苯丙酸
  参考文献：
  名称：

  5,6,7,8-TETRAHYDRO-IMIDAZO[1,5-A]PYRAZINE COMPOUNDS

  摘要：

  这项发明涉及式(I)的5,6,7,8-四氢咪唑[1,5-a]吡嗪衍生物，其中R1、R2、R3和R4如描述中所述，以及其盐，特别是药用可接受的盐，以及将这类化合物用作药物的用途；特别是作为促进睡眠的受体拮抗剂。

  公开号：

  US20110105514A1

文献信息

• Iridium‐Catalyzed Enantioselective Unbiased Methylene C(sp ³ )–H Borylation of Acyclic Amides
  作者：Yuhuan Yang、Lili Chen、Senmiao Xu

  DOI：10.1002/anie.202013568

  日期：2021.2.15

  We herein report amide directed enantioselective β‐C(sp3)−H borylation of unbiased methylene C−H bonds of acyclic amides enabled by iridium catalysis for the first time. The key to the success of this transformation relies on the careful selection of the combination of iridium precursor and chiral bidentate boryl ligands. A variety of functional groups are well‐tolerated, affording chiral β‐functionalized

  我们在此首次报道了铱催化的无环酰胺的无偏亚甲基CH键的酰胺定向对映选择性β-C（sp 3）-H硼化。该转化成功的关键在于精心选择铱前体和手性二齿硼基配体的组合。各种官能团均具有良好的耐受性，可提供良好至极好的对映选择性的手性β-官能化酰胺。我们还通过将C-B键立体定向转换为其他功能来演示当前方法的应用。
• Cyclic amine derivative or salt thereof
  申请人：Hayashibe Satoshi

  公开号：US20070197594A1

  公开（公告）日：2007-08-23

  Provided are compounds which are an NMDA antagonist having a broad safety margin and are useful as a treating agent or a preventing agent for Alzheimer's disease, cerebrovascular dementia, Parkinson's disease, ischemic apoplexy, pain, etc. Concretely provided are an amine derivative or its salt characterized in that the amine-containing structure A therein bonds to a 2- or 3-cyclic condensed ring (e.g., indane, tetralone, 4,5,6,7-tetrahydrobenzothiophene, 4,5,6,7-tetrahydrobenzofuran, 7,8-dihydro-6H-indeno[4,5-b]furan, 2,3-dihydro- 1 H-cyclopenta[1]naphthalene) via X 1 (bond or lower alkylene); and an NMDA antagonist containing it as an active ingredient thereof.

  提供的化合物是NMDA受体拮抗剂，具有广泛的安全边界，并可用作治疗或预防阿尔茨海默病、脑血管性痴呆、帕金森病、缺血性卒中、疼痛等药物。具体提供的是胺衍生物或其盐，其特点在于其中含有胺基结构A，通过X1（键或低碳烷基）与2-或3-环状紧缩环（例如茚烷、四氢萘酮、4,5,6,7-四氢苯并噻吩、4,5,6,7-四氢苯并呋喃、7,8-二氢-6H-茚并[4,5-b]呋喃、2,3-二氢-1H-环戊[1]萘烷）结合；以及含有它作为有效成分的NMDA受体拮抗剂。
• Design, synthesis and <i>in vitro</i> biological studies of novel triazoles with potent and broad-spectrum antifungal activity
  作者：Junhe Bao、Yumeng Hao、Tingjunhong Ni、Ruina Wang、Jiacun Liu、Xiaochen Chi、Ting Wang、Shichong Yu、Yongsheng Jin、Lan Yan、Xiaomei Li、Dazhi Zhang、Fei Xie

  DOI：10.1080/14756366.2023.2244696

  日期：2023.12.31

  Abstract A series of novel triazole derivatives containing aryl-propanamide side chains was designed and synthesised. In vitro antifungal activity studies demonstrated that most of the compounds inhibited the growth of six human pathogenic fungi. In particular, parts of phenyl-propionamide-containing compounds had excellent, broad-spectrum antifungal activity against Candida albicans SC5314, Cryptococcus

  摘要 设计并合成了一系列新型含芳基丙酰胺侧链的三唑衍生物。体外抗真菌活性研究表明，大多数化合物可抑制六种人类致病真菌的生长。特别是，部分含苯基丙酰胺的化合物对白色念珠菌SC5314、新型隐球菌22-21、光滑念珠菌537 和近平滑念珠菌22-20具有优异的广谱抗真菌活性，MIC 值在 ≤0.125 µg/ 范围内。毫升–4.0 微克/毫升。此外，化合物A1、A2、A6、A12和A15对耐氟康唑的白色念珠菌和耳念珠菌显示出抑制活性。还总结了初步的结构-活性关系（SAR）。此外，GC-MS分析表明A1、A3和A9通过抑制Cyp51干扰白色念珠菌麦角甾醇生物合成途径。分子对接研究阐明了A3和A9与 Cyp51的结合模式。这些具有低溶血活性和良好的 ADME/T 特性的化合物有望用于新型抗真菌药物的开发。
• CYCLIC AMINE DERIVATIVE OR SALT THEREOF
  申请人：Astellas Pharma Inc.

  公开号：EP1795524A1

  公开（公告）日：2007-06-13

  Provided are compounds which are an NMDA antagonist having a broad safety margin and are useful as a treating agent or a preventing agent for Alzheimer's disease, cerebrovascular dementia, Parkinson's disease, ischemic apoplexy, pain, etc. Concretely provided are an amine derivative or its salt characterized in that the amine-containing structure A therein bonds to a 2- or 3-cyclic condensed ring (e.g., indane, tetralone, 4,5,6,7-tetrahydrobenzothiophene, 4,5,6,7-tetrahydrobenzofuran, 7,8-dihydro-6H-indeno[4,5-b]furan, 2,3-dihydro-1H-cyclopenta[1]naphthalene) via X1 (bond or lower alkylene); and an NMDA antagonist containing it as an active ingredient thereof.

  本发明提供的化合物是一种具有广泛安全范围的 NMDA 拮抗剂，可作为阿尔茨海默病、脑血管痴呆症、帕金森病、缺血性脑中风、疼痛等的治疗剂或预防剂。具体而言，提供了一种胺衍生物或其盐，其特征在于其中的含胺结构 A 与 2-或 3-环缩合环（如茚满、四烯酮、4-环缩合环、5-环缩合环、6-环缩合环、7-环缩合环、8-环缩合环、9-环缩合环）结合、茚、四酮、4,5,6,7-四氢苯并噻吩、4,5,6,7-四氢苯并呋喃、7,8-二氢-6H-茚并[4,5-b]呋喃、2,3-二氢-1H-环戊并[1]萘）通过 X1（键或低级亚烷基）结合；以及含有它作为其活性成分的 NMDA 拮抗剂。
• Isoxazolyl substituted benzimidazoles
  申请人：CELLCENTRIC LTD

  公开号：US10118920B2

  公开（公告）日：2018-11-06

  A compound which is a benzimidazolyl isoxazole of formula (I): wherein: R0 and R, which are the same or different, are each H or C1-6 alkyl; R9, R9 and R9, which are the same or different, are each H or F; X is -(alkn-, -alk-C(═O)—NR—, -alk-NR—C(═O)— or -alk-C(═O)—; R1 is selected from —S(═O)2R′; a 4- to 6-membered, C-linked heterocyclic group which is unsubstituted or substituted; and an N-linked spiro group of the following formula: R2 and R2′, which are the same or different, are each H or C1-6 alkyl, or R2 and R2′ form, together with the C atom to which they are attached, a C3-6 cycloalkyl group; R3 and R3, which are the same or different, are each H, C1-6 alkyl, OH or F; R4 is phenyl or a 5- to 12-membered, N-containing heteroaryl group and is unsubstituted or substituted; alk is C1-6 alkylene; R′ is C1-6 alkyl; and n is 0 or 1; or a pharmaceutically acceptable salt thereof. The compound has activity in modulating the activity of p300 and/or CBP and is used to treat cancer, particularly prostate cancer.

  一种化合物，它是式(I)的苯并咪唑基异噁唑： 其中：R0和R（相同或不同）各自是H或C1-6烷基；R9、R9和R9（相同或不同）各自是H或F；X是-(alkn-、-alk-C(═O)-NR-、-alk-NR-C(═O)-或-alk-C(═O)-；R1 选自-S(═O)2R′；未取代或取代的 4 至 6 元 C 链杂环基团；以及下式的 N 联螺基：R2和R2′相同或不同，各自为H或C1-6烷基，或R2和R2′与所连接的C原子一起形成C3-6环烷基；R3和R3相同或不同，各自为H、C1-6烷基、OH或F；R4 是苯基或 5 至 12 元、含 N 的杂芳基，且是未取代或取代的；alk 是 C1-6 亚烷基；R′ 是 C1-6 烷基；n 是 0 或 1；或其药学上可接受的盐。该化合物具有调节 p300 和/或 CBP 活性的活性，可用于治疗癌症，特别是前列腺癌。